Fangzhou Inc. Incorporates DeepSeek Open-Source AI Model to Improve Online Healthcare
Fangzhou Inc. Integrates AI for Enhanced Healthcare Services
Successful Deployment of DeepSeek-R1
On February 8, 2025, Fangzhou Inc. (stock code: 06086.HK), known for its advancements in Internet healthcare solutions, announced a significant upgrade by integrating the DeepSeek-R1 open-source large language model into its operations. This development is anticipated to enhance the company’s service capabilities and streamline its processes, leading to more accurate and personalized healthcare solutions tailored for both patients and providers.
Leadership Vision
Dr. Xie Fangmin, the Founder, Chairman, and CEO of Fangzhou, emphasized the importance of this integration, stating that it represents a key milestone in their commitment to technological innovation. Dr. Xie expressed confidence that this upgrade would significantly enhance the platform’s capabilities, facilitating improved, more efficient healthcare services. The company aims to continue pioneering innovative solutions for its vast user base.
AI Technology Transforming Healthcare
The deployment of the DeepSeek-R1 model introduces advanced analytical and reasoning capabilities, which allow Fangzhou to provide data-driven decision support while ensuring user privacy and data security.
Benefits for Patients
- Enhanced Health Management: The platform offers in-depth analysis of medical reports, test results, and other health information, empowering healthcare providers to deliver informed medication guidance and post-diagnosis care plans.
- Personalized Solutions: By leveraging comprehensive health data, Fangzhou can offer customized care, addressing individual patient needs more effectively.
Benefits for Healthcare Providers
- Streamlined Processes: The AI-powered "AI Assistant" simplifies prescription reviews and patient management, enabling doctors to devote their attention to critical medical tasks.
- Improved Decision-Making: With science-based decision support integrated into its operations, the model aids in accurate diagnosis and development of optimized treatment plans.
Future Innovation Goals
Fangzhou’s focus in 2025 is on developing a range of specialized "AI Agent" applications. By leveraging the powerful analytical capabilities of DeepSeek-R1, the company aims to derive deeper insights from medical data. The goal is to drive further efficiencies and precision in the Internet healthcare landscape.
Overview of Fangzhou Inc.
Fangzhou Inc. stands as China’s leading online chronic disease management platform, boasting approximately 45.6 million registered users and a network of 217,000 doctors as of June 30, 2024. The company specializes in providing personalized medical care and precision medicine solutions tailored for patients with chronic illnesses.
DeepSeek: Advancing AI Solutions
Hangzhou DeepSeek Artificial Intelligence Basic Technology Research Co., Ltd., commonly known as DeepSeek, is a Chinese AI company focused on developing large language models (LLMs). Established in July 2023 and based in Hangzhou, Zhejiang, it is backed by the hedge fund High-Flyer. The company launched its first chatbot along with the DeepSeek-R1 model in January 2025.
Contact Information
For further inquiries or media interviews, representatives can reach out to Xingwei Zhao, Associate Director of Public Relations, via email.
Disclaimer: This article includes forward-looking statements, and actual results may vary due to various factors. Readers should not place excessive reliance on these statements.
For more details, visit Fangzhou’s Investor Relations page.
